Psoriasis – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of PsO for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
Clarivate Epidemiology’s PsO forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PsO over the forecast period?
- Of all people with PsO, how many have received a physician diagnosis?
- Of all people diagnosed with PsO, how many in each country across the developed world are drug-treated?
- Of all people diagnosed with symptomatic PsO, how many cases are mild, moderate, or severe?
- Of all people diagnosed with symptomatic PsO, how many have plaque PsO?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least ten years of forecast data for the following psoriasis subpopulations:
- Total prevalent symptomatic cases.
- Diagnosed symptomatic prevalent cases.
- Diagnosed symptomatic prevalent cases by severity.
- Diagnosed symptomatic prevalent cases by drug treatment status.
- Diagnosed symptomatic prevalent cases by subtype.
Note: Coverage may vary by country.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.